|
Match
|
Document |
Document Title |
|
|
7632926 |
Humanized monoclonal antibodies to hepatocyte growth factor
The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising...
|
|
|
7632501 |
Antibodies against monocyte chemotactic proteins
The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the...
|
|
|
7626002 |
Cytokine zalpha11 ligand antibodies
Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino...
|
|
|
7622555 |
Cytokine antagonist molecules
This invention relates to a novel protein (INSP052), herein identified as an immunoglobulin domain-containing cell surface recognition molecule and to the use of this proteins and nucleic acid...
|
|
|
7622559 |
Human monoclonal antibodies against interleukin 8 (IL-8)
Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal,...
|
|
|
7615213 |
Antibodies against human interleukin-13 and pharmaceutical compositions thereof
This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in...
|
|
|
7612182 |
Anti-IL-6 antibodies, compositions, methods and uses
The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at...
|
|
|
7608694 |
Antibody molecules having specificity for human IL-1β
The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
|
|
|
7608690 |
IL-B30 antibodies
Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using...
|
|
|
7605236 |
Antibodies that immunospecifically bind to B lymphocyte stimulator protein
The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for...
|
|
|
7601815 |
Anti-CCL27 antibodies
Novel CC chemokines from human, reagents related thereto including purified proteins, specific antibodies and nucleic acids encoding these chemokines are provided. Also provided are methods of...
|
|
|
7597886 |
Tumor necrosis factor-gamma
Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also...
|
|
|
7588761 |
Human antibodies that bind human TNFα
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d...
|
|
|
7585500 |
Fully human monoclonal antibodies to IL-13
The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies...
|
|
|
7585504 |
High affinity antibodies against HMGB1 and methods of use thereof
Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The...
|
|
|
7582297 |
Methods of treating respiratory conditions
The present invention provides prophylactic an tehrapeutic protocols desinged to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the...
|
|
|
7575893 |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
The present invention provides methods for producing humanized antibodies and increasing the yield of antibodies and/or antigen binding fragments when produced in cell culture. In one aspect of the...
|
|
|
7572441 |
Media and method for treating pathological syndrome
A medicament based on antibodies contains an activated form of monoclonal, polyclonal, or natural antibodies to interferon in low or ultra-low doses prepared by multiple consecutive dilutions and...
|
|
|
7572766 |
IFBMs to promote the specific attachment of target analytes to the surface of orthopedic implants
The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding...
|
|
|
7560112 |
Anti-il-6 antibodies, compositions, methods and uses
An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have...
|
|
|
7560533 |
Binding compounds specific for cysteine-rich soluble protein C23
Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of...
|
|
|
7544357 |
Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
The invention provides a method for treating an autoimmune disease in a subject by administering an interferon antagonist and a Flt3 ligand (Flt3L) antagonist. The invention also provides...
|
|
|
7541160 |
ELISA for VEGF
The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions,...
|
|
|
7541438 |
Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
A human monoclonal antibody useful for the treatment of various diseases caused by human connective tissue growth factor (CTGF) and preventing the onset of the above diseases; medicinal uses...
|
|
|
7541033 |
Humanized anti-IL-1β antibodies
The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof,...
|
|
|
7537932 |
Antibodies that bind purified mammalian FLT3 ligands
Flt3 ligand from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said ligand. Methods of using said reagents and diagnostic kits are...
|
|
|
7534572 |
Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
A method for treating and alleviating disease characterized by the expression of VEGF-D involving screening to find an organism with tumor cells expressing VEGF-D and administering an effective...
|
|
|
7534430 |
Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one...
|
|
|
7534870 |
Stable pharmaceutical composition comprising erythropoietin
The present invention provides a new stable pharmaceutical composition of erythropoietin (EPO) that is stabilized with a combination of a poloxamer polyol and a polyhydric alcohol.
|
|
|
7534431 |
Methods and compositions for administering therapeutic and diagnostic agents
Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.
|
|
|
7527790 |
Methods of reducing bone absorption comprising administering an antibody that binds OBM
Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided....
|
|
|
7524502 |
Modified anti-TNF alpha antibody
The invention relates to the modification of antibodies reactive to human tumor necrosis factor alpha (TNF alpha) to result in anti-TNF alpha antibodies that are substantially non-immunogenic or...
|
|
|
7521056 |
Stably tethered structures of defined compositions with multiple functions or binding specificities
The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments...
|
|
|
7514079 |
Antibodies that specifically bind to neurokinin B
The present invention relates to antibodies and related molecules that specifically bind to neurokinin B. Such antibodies have uses, for example, in the prevention and treatment of cancer as well...
|
|
|
7510709 |
Method of treating inflammatory disease by inhibition of IL-17 production
The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23). The invention further concerns the...
|
|
|
7504485 |
Human antibodies that bind human IL-12
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize...
|
|
|
7501497 |
TACI-immunoglobulin fusion proteins
Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The...
|
|
|
7495085 |
Antibodies against human or mouse IL-21 receptor
The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists...
|
|
|
7491516 |
Dual specificity antibodies and methods of making and using
Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or...
|
|
|
7491804 |
DNA dependent protein kinase catalytic subunit phosphorylation sites and antibodies thereto
The identification and use of two major DNA-PKcs autophosphorylation sites. Threonine (T) 2609 and Serine (S) 2056, including antibodies specific for phosphorylated T2609 and 52056. Peptides and...
|
|
|
7491391 |
Anti-IL-23 antibodies, compositions, methods and uses
An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using...
|
|
|
7491802 |
Anti-BAMBI antibody and diagnostic or remedy for colon cancer and liver cancer
The present invention provides an antibody (anti-BAMBI antibody) which recognizes a polypeptide having the amino acid sequence of SEQ ID No: 1 or a polypeptide having an amino acid sequence...
|
|
|
7482436 |
Human antihuman interleukin-6 antibody and fragment of antibody
A substance effective for treating immunopathy where interleukin 6 (IL-6) is involved is provided. A human anti-human IL-6 antibody and a human anti-human IL-6 antibody fragment having a high...
|
|
|
7465547 |
Methods for detecting human low molecular weight CD14
The present invention provides an antibody prepared using a peptide as an antigen, the peptide having 8 to 30 amino acid residues selected from an amino acid sequence at positions 1 to 68 of human...
|
|
|
7462696 |
Human antibodies that have MN binding and cell adhesion-neutralizing activity
The invention is composed of monoclonal human MN antibodies or MN antibody fragments that target the GEEDLP (SEQ ID NO: 118) repeat within the proteoglycan domain. The proteoglycan domain of the MN...
|
|
|
7446181 |
Antibodies that bind human Dickkopf-1 proteins
The invention relates to antibodies and immunologically active portions thereof that selectively bind a human Dickkopf-1 (Dkk-1) or Dkk-1-related polypeptide, and to compositions that contain such...
|
|
|
7435800 |
Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
Antibody to human IL-20 protein, a method for generation thereof and cells producing this antibody are disclosed. The antibody of the present invention has specificity to neutralizing...
|
|
|
7435799 |
TNF-α binding molecules
The present invention relates to TNF-α binding molecules and nucleic acid sequences encoding TNF-α binding molecules. In particular, the present invention relates to TNF-α binding molecules with...
|
|
|
7431927 |
TNFα-neutralizing antibodies
The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from...
|
|
|
7432360 |
Multi-dose erythropoietin formulations
The present invention is directed to multi-dose erythropoietin formulations for parenteral administrations. The formulations contain one or more of the following preservatives benzethonium...
|